464 related articles for article (PubMed ID: 31485826)
1. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X
J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930
[TBL] [Abstract][Full Text] [Related]
5. D-2-Hydroxyglutarate in Glioma Biology.
Chou FJ; Liu Y; Lang F; Yang C
Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Miller JJ; Shih HA; Andronesi OC; Cahill DP
Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
[TBL] [Abstract][Full Text] [Related]
8. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
9. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
[TBL] [Abstract][Full Text] [Related]
10. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
[TBL] [Abstract][Full Text] [Related]
12. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
13. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
14. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
Ohba S; Hirose Y
Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
16. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G
Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072
[TBL] [Abstract][Full Text] [Related]
17. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
[TBL] [Abstract][Full Text] [Related]
18. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
